TrialBritish journal of cancer2011

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study.

R Petrioli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.